Search
Porphobilinogen
go.drugbank.com/drugs/DB02272ExperimentalPorphobilinogen is a pyrrole involved in porphyrin metabolism. It is generated by the enzyme ALA dehydratase, and converted into hydroxymethyl bilane by the enzyme porphobilinogen deaminase.
Iboctadekin
go.drugbank.com/drugs/DB14920InvestigationalIboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18).
Girentuximab I-124
go.drugbank.com/drugs/DB15025InvestigationalGirentuximab I-124 is under investigation in clinical trial NCT01762592 (REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT).
Mesosulfuron-methyl
go.drugbank.com/drugs/DB15184ExperimentalMesosulfuron-methyl is under investigation in clinical trial NCT01118117 (A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery).
PL-3994
go.drugbank.com/drugs/DB15355InvestigationalPL-3994 is under investigation in clinical trial NCT01304628 (Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma).
Apazunersen
go.drugbank.com/drugs/DB16981InvestigationalApazunersen is an antisense oligonucleotide designed to target and inhibit the expression of UBE3A-AS. It is being investigated for the treatment of Angelman Syndrome.[L46772]
Burfiralimab
go.drugbank.com/drugs/DB18935InvestigationalBurfiralimab is under investigation in clinical trial NCT06306339 (A Study to Assess the Efficacy and Safety of Burfiralimab (Hzvsf-v13) and DMRD (Disease-modifying Antirheumatic Drug)).
Cinitapride
go.drugbank.com/drugs/DB08810InvestigationalIt is marketed in Spain and Mexico.
Synonyms: 4-Amino-N-(1-(3-cyclohexen-1-ylmethyl)-4-piperidyl)-2-ethoxy-5-nitrobenzamide2'-Deoxyuridine
go.drugbank.com/drugs/DB02256InvestigationalAn antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis.
Asm-024 cation
go.drugbank.com/drugs/DB19385InvestigationalAsm-024 cation is under investigation in clinical trial NCT01855230 (Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary